Neutralizing protease Nexin-1 in hemophilia patients on emicizumab improves thrombin generation
Véronique Arocas a), Laurence Venisse a), Yacine Boulaftali a), Stéphane Loyau a), Claire Flaujac b), Emmanuelle de Raucourt a) c) d), Marie-Christine Bouton a)
a) Université Paris Cité and Université Sorbonne Paris Nord, Inserm U1148-LVTS, Paris, France
b) Laboratoire de Biologie Médicale, Secteur Hémostase, Centre Hospitalier de Versailles (André Mignot), Le Chesnay-Rocquencourt, France
c) Centre de Ressources et Compétences des Maladies Hémorragiques Constitutionnelles Rares, Centre Hospitalier de Versailles (André Mignot), Le Chesnay-Rocquencourt, France
d) Département d’Hématologie, Hôpital Beaujon, Clichy, France
Highlights
• Blocking PN-1 has been shown to control bleeding and improve hemostasis in hemophilia.
• PN-1 blockade can accelerate the thrombin burst in blood from patients on emicizumab.
• PN-1 blockade has no impact on fibrinolysis in blood from patients on emicizumab.
• Patients receiving emicizumab may benefit from PN-1 blockade to improve hemostasis.